Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study

Author:

Tie Jeanne,Cohen Joshua D,Wang Yuxuan,Li Lu,Christie Michael,Simons Koen,Elsaleh Hany,Kosmider Suzanne,Wong Rachel,Yip Desmond,Lee Margaret,Tran Ben,Rangiah David,Burge Matthew,Goldstein David,Singh Madhu,Skinner Iain,Faragher Ian,Croxford Matthew,Bampton Carolyn,Haydon Andrew,Jones Ian T,S Karapetis Christos,Price Timothy,Schaefer Mary J,Ptak Jeanne,Dobbyn Lisa,Silliman Natallie,Kinde Isaac,Tomasetti Cristian,Papadopoulos Nickolas,Kinzler Kenneth,Volgestein Bert,Gibbs Peter

Abstract

ObjectiveFor patients with locally advanced rectal cancer (LARC), adjuvant chemotherapy selection following surgery remains a major clinical dilemma. Here, we investigated the ability of circulating tumour DNA (ctDNA) to improve risk stratification in patients with LARC.DesignWe enrolled patients with LARC (T3/T4 and/or N+) planned for neoadjuvant chemoradiotherapy. Plasma samples were collected pretreatment, postchemoradiotherapy and 4–10 weeks after surgery. Somatic mutations in individual patient’s tumour were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. We then designed personalised assays to quantify ctDNA in plasma samples. Patients received adjuvant therapy at clinician discretion, blinded to the ctDNA results.ResultsWe analysed 462 serial plasma samples from 159 patients. ctDNA was detectable in 77%, 8.3% and 12% of pretreatment, postchemoradiotherapy and postsurgery plasma samples. Significantly worse recurrence-free survival was seen if ctDNA was detectable after chemoradiotherapy (HR 6.6; P<0.001) or after surgery (HR 13.0; P<0.001). The estimated 3-year recurrence-free survival was 33% for the postoperative ctDNA-positive patients and 87% for the postoperative ctDNA-negative patients. Postoperative ctDNA detection was predictive of recurrence irrespective of adjuvant chemotherapy use (chemotherapy: HR 10.0; P<0.001; without chemotherapy: HR 22.0; P<0.001). Postoperative ctDNA status remained an independent predictor of recurrence-free survival after adjusting for known clinicopathological risk factors (HR 6.0; P<0.001).ConclusionPostoperative ctDNA analysis stratifies patients with LARC into subsets that are either at very high or at low risk of recurrence, independent of conventional clinicopathological risk factors. ctDNA analysis could potentially be used to guide patient selection for adjuvant chemotherapy.

Funder

The John Templeton Foundation

Virginia and D.K. Ludwig Fund for Cancer Research

The Conrad R. Hilton Foundation

NIH

The Sol Goldman Sequencing Facility at Johns Hopkins

National Health and Medical Research Council

Publisher

BMJ

Subject

Gastroenterology

Reference26 articles.

1. Howlader N , Noone A , Krapcho M , et al . SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute, 2016.

2. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer

3. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data

4. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Glynne-Jones;Ann Oncol,2017

5. National Comprehensive Cancer Network. Rectal Cancer (Version 3.2017). https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (accessed 1 Dec 2017).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3